ArticleJournal of hepatocellular carcinoma2026
Pre-TACE CK-MB/CK Ratio as an Independent Prognostic Biomarker in Advanced Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Primary liver cancer is a prevalent malignancy with a poor prognosis globally. Patients with advanced disease often undergo transarterial chemoembolization (TACE), yet simple and effective prognostic biomarkers are lacking. This study aimed to investigate the prognostic value of the serum creatine kinase isoenzyme MB to total creatine kinase (CK-MB/CK) ratio in patients with advanced primary liver cancer receiving TACE. Patients and Methods: A single-center retrospective cohort study was conducted, enrolling 158 patients between January 2021 and September 2024. Based on a CK-MB/CK ratio cutoff of 1, patients were categorized into an abnormal group (n=52) and a normal group (n=106). Comparative analysis of baseline characteristics, Kaplan-Meier survival analysis, and Cox proportional hazards regression modeling were performed to assess the relationship between the CK-MB/CK ratio and overall survival (OS). Results: Patients in the abnormal group exhibited lower body mass index (BMI), lower rates of previous hepatectomy, higher levels of tumor markers (including AFP and CEA), and poorer liver function indices compared to the normal group. Kaplan-Meier analysis revealed a significantly shorter OS in the abnormal group (median OS: 15.0 months vs 32.5 months, log-rank P < 0.001). Multivariate Cox regression analysis confirmed that an elevated CK-MB/CK ratio was an independent risk factor for OS, with a hazard ratio of 3.895 (95% confidence interval: 1.946-7.79). Conclusion: This retrospective single-center study suggests that a CK-MB/CK ratio >1 may serve as an independent and easily accessible marker of poor prognosis in patients with advanced liver cancer undergoing TACE. Further validation in larger cohorts is needed. This marker is cost-effective and readily available in routine clinical practice, showing potential for risk stratification. When combined with D-dimer, it may provide a practical tool for clinical prognostic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.